Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy

Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy

Sponsors

Lead Sponsor: AnaptysBio, Inc.

Source AnaptysBio, Inc.
Brief Summary

The purpose of this study is to determine ANB020 safety, tolerability and activity in adult patients with peanut allergy.

Detailed Description

This is a multi-center, randomized, double-blind, placebo-controlled, proof of concept study to assess the safety and tolerability of ANB020 in adult patients with peanut allergy.

Overall Status Completed
Start Date December 2016
Completion Date March 2018
Primary Completion Date March 2018
Phase Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Safety of ANB020 in adult patients with peanut allergy through study completion, an average of 60 days
Change in Laboratory Values through study completion, an average of 60 days
Secondary Outcome
Measure Time Frame
Clinical Scores of oral food challenge symptoms At pre-treatment and Day 14
Change in serum levels of specific cytokines through study completion, an average of 60 days
Describe Limited Pharmacokinetics through study completion, an average of 60 days
Describe Limited Pharmacokinetics through study completion, an average of 60 days
Enrollment 20
Condition
Intervention

Intervention Type: Drug

Intervention Name: ANB020

Description: ANB020

Arm Group Label: ANB020

Intervention Type: Drug

Intervention Name: Placebo

Description: Placebo

Arm Group Label: Placebo

Eligibility

Criteria:

Inclusion Criteria:

- Male and female patients with age >18 years and able to give informed consent.

- Patients with a confirmed clinically allergic response to peanut.

- Positive clinical reaction during the peanut oral food challenge and no clinical reaction during the placebo challenge

- Positive peanut allergy skin prick test >3 mm of the negative control and detectable serum peanut-specific Immunoglobulin E (IgE) levels by ImmunoCAP testing.

- Body mass index (BMI) of 18 to 36 kg/m2 (inclusive) and total body weight >50 kg (110 lb). BMI = weight (kg)/(height [m2]).

- Willing and able to comply with the study protocol requirements.

- Have the ability to read and understand the study procedures and have the ability to communicate meaningfully with the Investigator and staff.

- Women of childbearing potential, must have a negative serum pregnancy test at screening and Day 1, and be surgically sterile or using an acceptable method of contraception throughout the study and for 15 weeks after the last administration of investigational product. Postmenopausal patients defined as (1) aged over 45 years with at least 1 year of amenorrhea and levels of follicle stimulating hormone over 20 IU/L or (2) aged over 50 years with at least 1 year of amenorrhea.

- Male patients must be willing to use effective methods of contraception during the entire study period and for 15 weeks after the last administration of investigational product.

Exclusion Criteria:

- Have concomitant dermatological or medical condition(s) which may interfere with the Investigator's ability to evaluate the patient's response to the investigational product.

- Have experienced severe life-threatening anaphylactic reactions to peanuts within 6 months before screening (i.e., requiring an intensive care unit (ICU) admission).

- Positive clinical reaction observed during the placebo oral food challenge.

- Participation in any interventional study for the treatment of peanut and/or food allergies in the 12 months before screening.

- Have received any investigational product or been part of any interventional clinical study within a period of 3 months or 5 half-lives (whichever is longer) before screening.

- Have received systemic corticosteroids, nonsteroidal, immunosuppressant, or immunomodulating drugs treatments within 2 weeks before screening.

- Use of beta blockers, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, or calcium channel blockers within 2 weeks before screening.

- History of ischemic cardiovascular diseases.

- Use of biologics within 6 months before screening or subject is in build-up phase of allergen immunotherapy (excluding peanut) and has not reached maintenance dose.

- Have received antibiotic treatment within 1 week before screening.

- Have a history of hypersensitivity or allergic reactions following infusions of human blood or blood components.

- Have a history of hypersensitivity or allergic reactions a component of ANB020 formulation or the inactive ingredients (excipients).

- If female, are pregnant or lactating, or intend to become pregnant during the study period.

- Current diagnosis of asthma requiring Global Initiative for Asthma Assessment (GINA) Step 4 or higher treatment or asthma partially controlled or uncontrolled according to GINA classifications in the last three months before screening.

- History of a life threatening asthma attack within 1 year before screening (example: requiring an intensive care unit admission, intubation with mechanical ventilation).

- Other significant medical conditions that in the opinion of the Principal Investigator, prevent participation in the study.

- History of drug, alcohol or other substance abuse, or other factors limiting the ability to cooperate and to comply with the study protocol.

- Have any other physical, mental, or medical conditions which, in the opinion of the Investigator, make study participation inadvisable or could confound study assessments.

- Receipt of a live attenuated vaccine within 4 weeks before screening.

- Planned surgery during the study or 30 days before screening.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Overall Official
Last Name Role Affiliation
Marco Londei, MD Study Director AnaptysBio, Inc.
Location
Facility:
Stanford Univ. Medical Center | Palo Alto, California, 94305, United States
Asthma, Inc Clinical Research Center | Seattle, Washington, 98115, United States
Location Countries

United States

Verification Date

June 2018

Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 2
Arm Group

Label: ANB020

Type: Experimental

Description: ANB020, administration of ANB020

Label: Placebo

Type: Placebo Comparator

Description: Placebo, administration of Placebo

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Source: ClinicalTrials.gov